Encompass Health enters the post-earnings period with the Street firmly onside — and a cluster of insider selling that tells a more nuanced story about where management sees fair value.
The most striking feature of the past two weeks is the speed of the analyst response to the August 5–6 earnings release. Multiple firms raised their targets in lockstep: UBS went to $155 from $150, Truist lifted to $150 from $140, and TD Cowen moved to $140 from $125 — all while maintaining Buy or equivalent ratings. Barclays, already at Overweight, nudged its target to $144 from $140. With the consensus mean now running at $148, the stock at $122.10 implies roughly 21% upside to the average target, and every recent move has been upward. The earnings themselves justified the enthusiasm — the stock jumped nearly 13% on the day of the print and held virtually all of those gains through the five-day window, a clean double-digit post-earnings move that few healthcare names have matched this cycle.
The positioning backdrop reflects that confidence. Short interest is modest at 3.7% of free float — the kind of level that generates no squeeze pressure and no particular bearish signal. Borrowing costs have fallen sharply, dropping more than 40% on the week to just 0.24%, the lowest reading in the 30-day history. Availability is extremely loose at over 2,600% — meaning there are roughly 26 shares available to borrow for every one currently lent out, which leaves plenty of room for incremental shorts if sentiment were to sour. It hasn't. Options positioning leans bullish: the put/call ratio sits at 0.35, well below its 20-day average of 0.41, and sharply lower than the 1.0–1.1 range that prevailed through mid-July. That shift in options sentiment coincides almost exactly with the earnings date, suggesting hedges placed ahead of the print were unwound quickly once the result landed.
The Street's case for the stock centres on Encompass's dominant position in inpatient rehabilitation — a segment with structural demand tailwinds as the US population ages and post-acute care volumes grow. Bulls point to the company's Medicare Advantage execution, expanding facility count, and a technology-driven care model that supports revenue-per-discharge growth. The Piotroski F-score at the maximum reading of 9 and a mid-single-digit ROA underpin the quality argument. Bears flag leverage: the balance sheet carries meaningful debt, and reimbursement rate risk from CMS remains a live concern. At 19x trailing earnings and roughly 10.8x EV/EBITDA — multiples that have expanded over the past month — the stock is not cheap by historical standards for a healthcare services operator. Factor scores are unremarkable across the board, with short-score rank at 47 and sector score at 50, consistent with a stock that has re-rated to fair rather than cheap territory.
The insider picture complicates the bullish narrative. On August 10 — four days after the earnings pop — CEO Mark Tarr sold 173,148 shares for approximately $21.7 million. CFO Douglas Coltharp sold a further 18,869 shares for $2.4 million the same day. General Counsel John Darby sold 8,906 shares for $1.1 million. Combined, the net insider outflow over the past 90 days totals roughly $28.2 million in value. Insider selling after a sharp earnings-driven rally is not unusual — much of this likely reflects planned disposals of vested equity — but the concentration of large sales at the $125–$126 level, precisely where the stock ran to on the earnings day, is worth noting. Management appears to have used the spike as a distribution window.
Wellington Management added nearly 464,000 shares through June, AllianceBernstein added 754,000, and Goldman Sachs Asset Management built a position of over 1.4 million shares in the same period — all meaningful institutional accumulation that predates the August earnings move. The next catalyst is the Q3 print, scheduled for October 30. Between now and then, the focus shifts to whether same-store volume trends hold, and whether any Medicare rate guidance from CMS changes the reimbursement calculus that underpins the bull case.
See the live data behind this article on ORTEX.
Open EHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
